理解心血管疾病一级与二级预防中的治疗-亚组效应:基于个体患者数据荟萃分析的探索
该研究系统检索纳入同时包含一级和二级预防人群的个体患者数据荟萃分析,提取常见心血管预防干预对患者重要结局的相对风险(RR)及95%CI,并估计一级与二级预防人群的RR比值。共纳入5项IPD荟萃分析、524570名参与者,方法学质量总体低至中等。结果显示任何评估结局均无预防类别间的亚组效应,提示临床实践指南可基于个体心血管风险评估给出推荐而不必区分一级或二级预防队列。
要点
- 常见心血管预防干预的相对效应在一级与二级预防人群间无显著亚组交互。
- 指南可基于个体ASCVD风险评估推荐,无需区分一级或二级预防队列。
- 需开发适用于两类人群的可靠ASCVD风险评估工具。
核心结论
- 常见预防干预在一级与二级心血管预防队列间无显著治疗-亚组交互,指南可基于个体心血管风险评估推荐而不必区分预防类别。
研究设计与样本
- 系统检索个体患者数据(IPD)荟萃分析,纳入同时包含一级和二级预防人群的研究。
- 共识别5项 eligible IPD 荟萃分析,代表524570名参与者。
- eligibility评估、数据提取和偏倚风险评估独立双人完成。
- 提取干预对患者重要结局的相对风险(RR)及95%CI,并估计一级与二级预防人群的RR比值。
- 质量评估总体方法学质量低至中等。
主要发现
- 在任何评估结局中均未发现预防类别间的亚组效应。
关键数值与推荐
- 共纳入5项IPD荟萃分析,合计524570名参与者。
- 方法学质量总体低至中等。
- 所有评估结局均无预防类别间亚组效应。
临床怎么用
- 临床实践指南可基于个体心血管风险评估提供推荐,而不必区分一级或二级预防队列。
- 需开发适用于一级和二级预防人群的可靠ASCVD风险评估工具。
局限性
- 纳入的IPD荟萃分析方法学质量总体低至中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Recommendations for preventing cardiovascular (CV) disease are currently separated into primary and secondary prevention. We hypothesize that relative effects of interventions for CV prevention are not different across primary and secondary prevention cohorts. Our aim was to test for differences in relative effects on CV events in common preventive CV interventions across primary and secondary prevention cohorts. METHODS AND RESULTS: A systematic search was performed to identify individual patient data (IPD) meta-analyses that included both primary and secondary prevention populations. Eligibility assessment, data extraction, and risk of bias assessment were conducted independently and in duplicate. We extracted relative risks (RR) with 95% confidence intervals (95% CI) of the interventions over patient-important outcomes and estimated the ratio of RR for primary and secondary prevention populations. We identified five eligible IPDs representing 524,570 participants. Quality assessment resulted in overall low-to-moderate methodological quality. We found no subgroup effect across prevention categories in any of the outcomes assessed. CONCLUSION: In the absence of significant treatment-subgroup interactions between primary and secondary CV prevention cohorts for common preventive interventions, clinical practice guidelines could offer recommendations tailored to individual estimates of CV risk without regard to membership to primary and secondary prevention cohorts. This would require the development of reliable ASCVD risk estimators that apply across both cohorts.
引用
- Torres Roldan VD, Ponce OJ, Urtecho M, et al. Understanding treatment-subgroup effect in primary and secondary prevention of cardiovascular disease: An exploration using meta-analyses of individual patient data. J Clin Epidemiol. 2021. PMID: 34400257. doi:10.1016/j.jclinepi.2021.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。